Session » Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1343

A Novel Autoantibody Against DNA Damage Binding Protein-1 in Idiopathic Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 1347

A Semi-Quantitative Whole Body Magnetic Resonance Imaging Assessment Tool to Define Musculoskeletal Abnormalities in Patients with Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1333

Abnormal Function of High Density Lipoproteins in Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1340

Anti-Aminoacyl-tRNA-Synthetase Antibodies Which Are Positive By ELISA but Negative By RNA-Immunoprecipitation Suggest Different Antigen Recognition and Clinical Relevance Different from Typical Anti-Synthetase Syndrome

9:00AM-11:00AM: Abstract Number: 1346

Anti-NT5c1A Autoantibodies As Biomarkers in Inclusion Body Myositis

9:00AM-11:00AM: Abstract Number: 1344

Anti-Splicing Factor Proline/Glutamine-Richautoantibodies Rarely Co-Exist with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies in a Cohort of Dermatomyositis Patients from the United States

9:00AM-11:00AM: Abstract Number: 1345

Association of HLA-DRB1*0301 with Antisynthetase Syndrome in Spanish Patients

9:00AM-11:00AM: Abstract Number: 1341

Autoantibodies to Mi-2 Alpha and Mi-2 Beta in Patients with Myositis

9:00AM-11:00AM: Abstract Number: 1353

Autophagy Marker LC3 Accumulates in Immune-Mediated Necrotizing Myopathy Muscle Fibres

9:00AM-11:00AM: Abstract Number: 1350

Elevated Serum Levels of Soluble CD146 and CD146 Autoantibody in Patients with Polymyositis/Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1335

Extracellular Vesicles Induce Pro-Inflammatory Cytokines in Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1336

Functional, Radiographic and Serologic Correlates of Anti-SSA52 Kd – Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1351

In Situ Dendritic Cell Characterization in Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1334

Low Density Granulocytes As Biomarkers of Disease Activity and Damage in Patients with Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1352

Low Density Granulocytes in Idiopathic Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 1331

Moving from Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody to Anti-Melanoma Differentiation-Associated Gene 5 Syndrome

9:00AM-11:00AM: Abstract Number: 1337

Myocardial Fatty Acid Metabolism and Perfusion Mismatch in Scintigraphy Predicts Worse Prognosis in Clinically Amyopathic Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1339

Myositis Specific Anti-Histidyl tRNA Synthetase (HisRS) Autoantibodies Display High Reactivity Against Hisrs Conformational Epitopes and Associate with Lung and Joint Involvement

9:00AM-11:00AM: Abstract Number: 1342

Myositis Specific Antibodies Measured Using a Novel Particle Based Multi-Analyte Assay Resemble Myositis Subsets By Principle Component Analysis

9:00AM-11:00AM: Abstract Number: 1332

Proteomic Discovery Analysis Identifies Unique Proteins and Pathways Correlating with Different Clinical Activity and Damage Measures in Juvenile Dermatomyositis (JDM)

9:00AM-11:00AM: Abstract Number: 1348

Quantitative High Throughput Screening of Small Molecules to Inhibit Interferon-Stimulated Major Histocompatibility Complex Class I in Myositis Muscle

9:00AM-11:00AM: Abstract Number: 1349

Rnaseq of Peripheral Blood Mononuclear Cells from Juvenile Dermatomyositis, Necrotizing Myopathy and Controls Are an Aid in Diagnosis

9:00AM-11:00AM: Abstract Number: 1338

Validation of the Diagnostic Accuracy of Myositis-Related Antibodies in a Large Patient-Cohort

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].